Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Noland

Neurology Tucson, AZ Medical Doctor

NPI 1922077668 CMS profile 223654

2450 E River Road, Tucson, AZ 85718

Open in the dashboard

General payments

$6,243

342 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Noland of Tucson, AZ is reported in the CMS Open Payments database as having received $6,243 across 342 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,749 81
2024 General $1,246 64
2023 General $1,076 66
2022 General $677 40
2021 General $690 43
2020 General $559 32
2019 General $246 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Noland
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to William Noland were reported at $1,749. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year William Noland Neurology median Middle half National median
2019 $246 $474 $118–$2,177 $163
2020 $559 $367 $82–$2,309 $114
2021 $690 $438 $104–$2,547 $132
2022 $677 $442 $103–$2,388 $149
2023 $1,076 $464 $119–$2,312 $160
2024 $1,246 $468 $119–$2,323 $164
2025 $1,749 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,278 67 payments
  2. Allergan Inc. $947 58 payments
  3. UCB, Inc. $567 33 payments
  4. Novartis Pharmaceuticals Corporation $261 14 payments
  5. EMD Serono, Inc. $252 11 payments
  6. Amgen Inc. $245 12 payments
  7. Alexion Pharmaceuticals, Inc. $210 5 payments
  8. Lilly USA, LLC $164 10 payments
  9. Biogen, Inc. $154 9 payments
  10. Genzyme Corporation $152 3 payments
  11. Other $2,013 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,143 341 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX Hyperhydrosis $978 59 payments
  2. BOTOX Botox Therapeutic $508 25 payments
  3. QULIPTA $417 22 payments
  4. UBRELVY $381 21 payments
  5. Briviact $229 18 payments
  6. ULTOMIRIS $194 4 payments
  7. BOTOX Neuroscience $183 10 payments
  8. KESIMPTA $181 10 payments
  9. AIMOVIG $167 8 payments
  10. PONVORY $138 5 payments
  11. Other $3,279 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

4,896

Median for Neurology: 833

Drug cost

$2,677,684

Median for Neurology: $202,670

Branded share of claims

26.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 92 $1,030,247
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 17 $569,568
Botox Onabotulinumtoxina Brand 247 $331,404
Rebif Interferon Beta-1a/Albumin Brand 21 $212,790
Tecfidera Dimethyl Fumarate Brand 11 $106,180
Copaxone Glatiramer Acetate Brand 14 $81,516
Fingolimod Fingolimod Hcl Brand 36 $64,810
Glatiramer Acetate Generic 30 $62,441
Nurtec Odt Rimegepant Sulfate Brand 18 $35,089
Ubrelvy Ubrogepant Brand 24 $29,254

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$1,461,262

Of which drugs: $1,347,824

Medicare patients

511

Average age 73

Services billed

46,382

265 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 58%
Ischemic heart disease 30%
Depression 30%
Diabetes 25%
Chronic kidney disease 24%
Osteoporosis 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 77 25,437 $122,228
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 Office 25 191 $221
Injection, gadobutrol, 0.1 ml A9585 Office 15 120 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $200
$200 247 25,437
UBRELVY
  • AbbVie, Inc. $74
$74 24 —
Briviact
  • UCB, Inc. $73
$73 — —
QULIPTA
  • AbbVie, Inc. $71
$71 — —
Fintepla
  • UCB, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record